Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249483 · ClinicalTrials.gov registry record · Phase 2
Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals
A Phase 2 study of Cocaine-Related Disorders, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00249483 is a Phase 2 study of Cocaine-Related Disorders that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 150 participants, above the 55-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (173% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00249483, a Phase 2 study of Cocaine-Related Disorders, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Preliminary research has shown that venlafaxine, a medication currently used for treating depression, may also discourage cocaine use in depressed individuals. This study will evaluate the effectiveness of venlafaxine in reducing cocaine use and alleviating depression in individuals addicted to cocaine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Venlafaxine
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 1999-10 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249483
The ClinicalTrials.gov registry entry for NCT00249483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 55-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (173% higher). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00249483 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00249483 about?
NCT00249483 is a clinical study titled "Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals". Preliminary research has shown that venlafaxine, a medication currently used for treating depression, may also discourage cocaine use in depressed individuals. This study will evaluate the effectiveness of venlafaxine in reducing cocaine use and alleviating depression in individuals addicted to coca...
What is the current status of trial NCT00249483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 1999-10. Estimated completion is 2005-02.
What conditions does trial NCT00249483 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders.
What interventions are being tested in trial NCT00249483?
The interventions under investigation include: Placebo (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00249483?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00249483 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
COMPLETED · Phase 2
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Pharmacological Modulation of Cocaine Effects - 1
COMPLETED · Phase 2
-
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
COMPLETED · Phase 2
-
Risperidone Treatment in Dually-Diagnosed Individuals - 2
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.